Market Snapshot

Market Snapshot

Market Overview

Market Overview

The COVID-19 pandemic has devastated economic and public health, and healthcare industry has been busy developing the vaccines, antivirals, and supportive treatments which is a time-consuming process in order to develop drugs and get approval.

Unlike other industries, COVID-19 pandemic has further created opportunities for the biotechnology companies to utilise the opportunity and showcase the capabilities of computer aided drug design and development.

Increasing cost of drug development and lack of new chemical entities are the growing concerns for new development of drugs. COVID-19 is providing greater opportunities for drug repurposing activities and companies are increasingly using computer aided drug discovery to study the existing drug effects on COVID-19.

There have been major developments in In-Silico Drug repurposing across the world, where they develop new use to an old existing drug, which is a cost effective strategy to develop drug for COVID-19.

With the outbreak of SARS-CoV-2 virus causing the COVID-19 pandemic, and researchers are turning towards computer simulations and AI technologies to identify potential treatments.

For instance, in June 2020, Delta 4, a biotech company has applied its drug discovery platform to identify and shortlisting potential COVID-19 drug using computer models

Increasing laboratories, researchers and drug development organisations are using of AI(artificial Intelligence), quantum mechanical scoring, and other computer simulation and genomic analysis methodologies.

For instance, In June 2020, Ennaid Therapeutics are developing antiviral drugs for COVID-19 using AI-based drug discovery platforms. ENU200, a repurposed orally deliverable antiviral drug is able to treat up to 80% of asymptomatic, mild to moderate cases of COVID-19 viral infections. The company yet to avail approvals for use in COVID-19.

Uncover key market trends, investment insights, and global economic impacts driving this industry's growth
Download Free Overview Report

Porter 5

Market Segmentation

Company Performance

Financial values in the chart are available after report is purchased.

Our Company Coverage

Our comprehensive company performance report offers a detailed analysis of critical factors for our clients' industry insights. It covers key financial metrics, such as revenue, profit, and profit margin, providing a clear financial overview. We also assess the company's structure by identifying key subsidiaries and top industry competitors, conducting a thorough SWOT analysis to reveal strengths, weaknesses, opportunities, and threats. The report includes an in-depth income statement for financial assessment and a credit analysis for evaluating creditworthiness. Industry-specific data and benchmarks enable clients to compare performance, providing actionable insights for strategic decisions and competitive advantages.

Corporate Information

Main activities
Number of employees
Key executives
Company Description
Similar companies
Ownership details
Financial Performance Charts
Top Competitors
Similar companies
Ownership details
Financial Performance Charts
Top Competitors

Corporate Information

Income statement
Credit analysis
Credit analysis
Benchmark score

Depending on the size and type of the organisation we may also provide:

News: Business/financial results, investments and deals
Reports: Annual reports, broker reports
M&A: Information on past deals, deal intents
Discover the industry's latest trends, global economic factors, and impactful investments driving its expansion.
Download Free Sample
Download Free Sample

Table of Contents

Table of Contents

1. Research Methodology and Scope

2. Executive Summary

3. Market Dynamics

        3.1 Drivers

        3.2 Restraints

        3.3 Porters Five Forces Analysis

4. Industry Regulations

5. Competitive Landscape

6. Computer Simulated Drug Discovery Market by Workflow

        6.1 Target Identification

                 6.1.1 Bioinformatics

                 6.1.2 Reverse Docking

                 6.1.3 Protein StructurePrediction

        6.2 Target Validation

        6.3 Lead Discovery

                 6.3.1 Library Design

                 6.3.2 Pharmacophore

        6.4 Pre-Clinical Tests

        6.5 Clinical Trials

7. Computer Simulated Drug Discovery Market by Product

        7.1 Software

        7.2 Cloud

        7.3 Consultancy as a Service

8. Computer Simulated Drug Discovery Market by Software

        8.1 Molecular Modelling and de NovoDrug Design Software

        8.2 Pharmacophore Modelling Software

9. Computer Simulated Drug Discovery Market by End-User

        9.1 Contract Research Organisations

        9.2 Pharmaceutical Industry

        9.3 Academic and Research Institutes

        9.4 Others

10. Computer Simulated Drug Discovery Market by Region

        10.1 North America

                 10.1.1 United States

                 10.1.2 Canada

                 10.1.3 Mexico

        10.2 Europe

                 10.2.1 United Kingdom

                 10.2.2 Spain

                 10.2.3 Italy

                 10.2.4 Russia

                 10.2.5 Germany

                 10.2.6 Rest of Europe

        10.3 Asia-Pacific

                 10.3.1 China

                 10.3.2 India

                 10.3.3 Japan

                 10.3.4 Australia

                 10.3.5 South Korea

                 10.3.6 Rest of Asia-Pacific

        10.4 South America

                 10.4.1 Brazil

                 10.4.2 Rest of South America

        10.5 Middle East and Africa

11. Company Profiles

        11.1 Albany Molecular Research

        11.2 Charles River

        11.3 Evotech

        11.4 Simulation Plus

        11.5 Selvita

        11.6 Dassault System

        11.7 WuXi AppTec

        11.8 Certara USA, Inc

        11.9 Collaborative Drug Discovery Inc

        11.10 PerkinElmer, Inc

12. Appendix

Research Methodology

Segmentation by Product

Drug designing and development are the key stages in the In-Silico drug discovery process that allow for the clinical trials make it to the market.

Over the last three decades software based drug development has played an important role in the development of bioactive compounds.

Structure-based drug design, molecular modelling, structure-based virtual screening, ligand interaction, and molecular dynamics are the key software methods of developing a drug.

Computational methods such as docking confer interaction of small molecules with structural macro-molecules are used in identification and lead optimisation.

Currently, the software methods are exhibiting a domineering role in different phases of drug discovery, especially in biomedicine sciences.

New technologies such as virtual reality and AI are further adding enhanced opportunities for the drug discovery.

For instance, in May 2020, Nanome, Inc., a virtual reality (VR) startup and In-Silico Medicine, an artificial intelligence company have published a paper on developing 10 potential small molecule inhibitors targeting the SARS-CoV-2 main protease using AI.

In-Silico has previously been successful in designing small molecule drugs for a wide range of human diseases, such as cancer, fibrosis, and immunological diseases.

Segmentation by Geography

United States and China is being one of the prominent region for In-Silico drug discovery market.

China is increasingly contributing to the industry in recent years. The growth and increasing adoption in the country is mainly due to increasing development of various products by international giants and local players.

The country is expected to showcase strong growth over the forecast period at aCAGR of around 11%.

The anticipated growth in the country is mainly due to various government initiatives to incorporate drug discovery methodologies as a standard approach in their healthcare systems.

InOctober 2019, In-Silico Medicine in collaboration with Jiangsu Chia Tai Fenghai Pharmaceutical (CTFH) has signed a dual-program discovery, which worth up to USD 200 million.

In-Silico has recently raised USD 37 million in a series B round to further enhance AI-based pharma partnerships from China-based Qiming Venture Partners besides Eight Roads, Sinovation Ventures, Baidu Ventures, Deep Knowledge Ventures, F-Prime Capital, Lilly AsiaVentures, and others.

Major Players

Charles River
Charles River
WuXi AppTec
WuXi AppTec